Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amgen
Denosumab Osteoporosis Trial Finds Patients Transitioned from Alendronate Fosamax to Denosumab Achieved Significantly Greater Gains in Bone Mineral Density versus Those Continuing on Alendronate
October 2nd, 2008
Amgen (NASDAQ:AMGN) announced full data results from a non-pivotal Phase 3 head-to-head, double-blind trial comparing bone mineral density (BMD) gains in postmenopausal women with low bone mass who transitioned from weekly oral alendronate (Fosamax(R)) to denosumab versus those who continued alendronate therapy. In addition, patient preference data from another non-pivotal head-to-head trial comparing denosumab to weekly oral alendronate were announced at the 2008 American Society of Bone and Mineral Research (ASBMR) Annual Meeting in Montreal. "Data from these trials highlight the potential for a new treatment option for the millions of postmenopausal women worldwide...
Source: Women's Health Weekly (2008-10-02)
|
